Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.74 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31126461 | 1.00 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL17320209 | 0.92 | ALOX5 (0.85) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL6926815 | 0.92 | ALOX5 (0.85) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL4538024 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL12297865 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL12297401 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL12297429 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL2755675 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL10072694 | 0.85 | ALOX5 (0.74) | ALOX5AMY1ARAB9AMEN1KMT2A | |
| SCHEMBL1819906 | 0.85 | RAB9A (0.78) | ALOX5AMY1ARAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | claimed |
| US-9987256-B2 | CFTR corrector for the treatment of genetic disorders affecting striated muscle | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-06-05 | — | — | US | claimed |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | claimed |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2015-11-19 | — | — | US | claimed |
| EP-2925317-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | Università Degli Studi Di Padova (IT) | 2015-10-07 | — | — | EP | claimed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086687-A1 | A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | ALOX5 4303/4885AMY1A 1553/4885RAB9A 687/4885 |
| US-20150328217-A1 | A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | ALOX5 4093/4885AMY1A 1760/4885RAB9A 789/4885 |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | CFTR, NEDD8, SCNN1B | ALOX5 4661/4885AMY1A 4147/4885RAB9A 1472/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | ALOX5 3935/4885AMY1A 4329/4885RAB9A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.